Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates

This publication has 28 references indexed in Scilit:

• Is Activity against “Atypical” Pathogens Necessary in the Treatment Protocols for Community‐Acquired Pneumonia? Issues with Combination Therapy
  Clinical Infectious Diseases, 2008
• Emergence of 19A as Virulent and Multidrug Resistant Pneumococcus in Massachusetts Following Universal Immunization of Infants With Pneumococcal Conjugate Vaccine
  The Pediatric Infectious Disease Journal, 2007
• Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
  Clinical Infectious Diseases, 2007
• Molecular Epidemiology of Multiresistant Streptococcus pneumoniae with Both erm (B)- and mef (A)-Mediated Macrolide Resistance
  Journal of Clinical Microbiology, 2004
• Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children
  The Pediatric Infectious Disease Journal, 2003
• Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine
  New England Journal of Medicine, 2003
• The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections
  Journal of Antimicrobial Chemotherapy, 2002
• The epidemiology of respiratory tract infections
  Seminars in Respiratory Infections, 2000
• The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
  Journal of Antimicrobial Chemotherapy, 2000
• Emergence of Multiply Resistant Pneumococci
  New England Journal of Medicine, 1978